Results 11 to 20 of about 60,957 (246)
Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents
Biomedical Papers, 2021 Myeloproliferative neoplasms (MPN), are clonal hematopoietic stem cell (HSC) disorders driven by gain-of-function mutations in JAK2 (JAK2-V617F), CALR or MPL genes.
Jan Stetka, Radek C. Skoda
doaj +1 more source
Iraqi Journal of Hematology, 2020 BACKGROUND: Chronic inflammation has been suggested to contribute to the pathogenesis of thrombosis in polycythemia vera (PV) as it triggers in vivo activation of platelets, leukocytes, and endothelial cells, which are all of major importance during ...
Ibrahim Abdullah Mahmood +2 more
doaj +1 more source
Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera [PDF]
Терапевтический архив, 2016 Aim. To evaluate the efficiency of interferon (IFN) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Subjects and methods. A total of 61 patients (41 with ET and 20 with PV) were examined.
M A Sokolova +12 more
doaj +1 more source
Detection of activating mutations in RAS/RAF/MEK/ERK and JAK/STAT signaling pathways [PDF]
Терапевтический архив, 2020 Issue.The study of activating mutations (NRAS,KRAS,FLT3,JAK2,CRLF2genes) of RAS/RAF/MEK/ERK and JAK/STAT signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) in adult patients which are included in Russian multicenter clinical trials ...
K. I. Zarubina +13 more
doaj +1 more source
Leptin Stimulates Both JAK2-dependent and JAK2-independent Signaling Pathways [PDF]
Journal of Biological Chemistry, 2008 Leptin controls body weight by activating the long form of the leptin receptor (LEPRb). Janus kinase 2 (JAK2) is associated with LEPRb and autophosphorylates in response to leptin. JAK2 also phosphorylates LEPRb, STAT3, and multiple other downstream molecules.
Lin, Jiang, Zhiqin, Li, Liangyou, Rui
openaire +2 more sources
JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients
Hematology/Oncology and Stem Cell Therapy, 2023 Background: Mutations in JAK2/STAT5 proliferation pathway genes are key in the diagnosis of myeloproliferative neoplasms (MPNBCR/ABLneg), with JAK2V617F being found in 50-97% of MPNBCR/ABLneg subtypes.
Karen L. Shires +4 more
doaj +1 more source
Blood cell activation as an indicator of prothrombogenesis in polycythemia vera: Case control study
Iraqi Journal of Hematology, 2019 BACKGROUND: Polycythemia vera (PV) is a chronic myeloproliferative stem cell disease usually combined with JAK2 mutation. Active JAK2 mutation directly promote platelets and granulocytes activation and indirectly initiate endothelial activation.
Ibrahim A Mahmood +2 more
doaj +1 more source
Hepatology, EarlyView., 2022 KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou +15 more
wiley +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC
OncoImmunology, 2017 Programmed death ligand 1 (PD-L1) functions as a key immune inhibitory factor by binding with its receptor, programmed death 1 (PD-1), to induce immune cell dysfunction and escape of the immune system.
Chengzhong Lin +11 more
doaj +1 more source